BNP Paribas Financial Markets Buys 7,016 Shares of Omeros Co. (NASDAQ:OMER)

BNP Paribas Financial Markets increased its position in shares of Omeros Co. (NASDAQ:OMER) by 130.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,388 shares of the biopharmaceutical company’s stock after acquiring an additional 7,016 shares during the quarter. BNP Paribas Financial Markets’ holdings in Omeros were worth $49,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in shares of Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after purchasing an additional 31,081 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Omeros during the 2nd quarter worth approximately $105,000. SG Americas Securities LLC bought a new position in Omeros in the third quarter valued at approximately $80,000. SPC Financial Inc. acquired a new position in shares of Omeros in the third quarter valued at approximately $77,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Omeros by 4.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after acquiring an additional 18,454 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on OMER. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Thursday, November 14th. Rodman & Renshaw started coverage on Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price on the stock. Finally, RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Omeros Stock Performance

NASDAQ:OMER opened at $10.24 on Friday. Omeros Co. has a 52-week low of $2.61 and a 52-week high of $13.60. The company has a market cap of $593.41 million, a P/E ratio of -4.43 and a beta of 1.97. The stock’s 50-day simple moving average is $6.96 and its 200 day simple moving average is $5.13.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.